Search Result

Results for "

Colo-205

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Apoptosis (2) Autophagy (4) c-Kit (3) CDK (3) COX (1) Endogenous Metabolite (1) ERK (1) FGFR (6) IGF-1R (1) Microtubule/Tubulin (3) Necroptosis (1) P-glycoprotein (1) PDGFR (3) PROTACs (2) Raf (3) RET (3) Tie (3) VEGFR (6)
By Research Areas:	Cancer (26) Inflammation/Immunology (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143904

PROTAC TTK degrader-1	PROTACs	Cancer
PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-143905

PROTAC TTK degrader-2	PROTACs	Cancer
PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC₅₀ values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .

HY-143385

Cdc7-IN-12	CDK	Cancer
Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor with an IC₅₀ of <1 nM. Cdc7-IN-12 shows antiproliferative activities with IC₅₀ of 100-1000 nM in COLO205 cells. Cdc7-IN-12 has the potential for the research of cancer .

HY-153704

CDK4/6-IN-17	CDK	Cancer
CDK4/6-IN-17 (compound 12) is an orally active CDK4/6 inhibitor with IC₅₀ ranging of 10-100 nM in BE(2) cells. CDK4/6-IN-17 inhibits tumor growth in COLO205 xenograft model .

HY-143432

Cdc7-IN-18	CDK	Cancer
Cdc7-IN-18 (compound 1-2) is a potent CDC7 inhibitor with an IC₅₀ of 1.29 nM for Cdc7/DBF4 enzyme. Cdc7-IN-18 shows antiproliferative activities with IC₅₀ of 53.62 nM in COLO205 cells .

HY-149366

ABCB1-IN-1	P-glycoprotein	Cancer
ABCB1-IN-1 (compound 3) is a potent ABCB1 inhibitor. ABCB1-IN-1 induces cell apoptosis. ABCB1-IN-1 bearing 1-benzylimidazole has IC₅₀ values of 1.26 μM and 2.21 μM for Colo205 and Colo320 cells, respectively .

HY-151367

SHR2415	ERK	Cancer
SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC₅₀ values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC₅₀ value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .

HY-155764

COX-1/2-IN-4	COX	Cancer
COX-1/2-IN-4 (compound 2b) is anCOX inhibitorwith IC₅₀ values of 0.239 μM and 0.191 μM for COX-1 enzyme and COX-2 enzyme , respectively. COX-1/2-IN-4showsmoderateanticanceractivity against COLO205 and B16F1 cancer cell lines with IC₅₀ values of 30.79 and 74.15 μM, respectively .

HY-B1714A

NSC 601980	Others	Cancer
NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.

HY-B1714

NSC 601980 analog	Others	Cancer
NSC 601980 analog is the analog of the NSC601980, NSC601980 shows antitumor activity in the yeast screening experiment, which can inhibit cell proliferation in the COLO 205 and HT29 with Log GI 50 of -6.6 and -6.9 respectively.

HY-112898

DC1SMe	ADC Cytotoxin	Cancer
DC1Sme, a DC1 derivative, exhibits IC₅₀ values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.

HY-N6002

3'-Hydroxypterostilbene 1 Publications Verification	Apoptosis Autophagy	Cancer
3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC₅₀s of 9.0, 40.2 and 70.9 µM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer .

HY-149214

Anticancer agent 100

Others Cancer

Anticancer agent 100 is a derivative of tetracaine with anti-cancer activity and can be used in cancer research .
HY-149216

Anticancer agent 103

Others Cancer

Anticancer agent 103 (Compound 2k) is a potent anticancer agent .

Anticancer agent 100	Others	Cancer
Anticancer agent 100 is a derivative of tetracaine with anti-cancer activity and can be used in cancer research .

Anticancer agent 103	Others	Cancer
Anticancer agent 103 (Compound 2k) is a potent anticancer agent .

HY-115737

L-threo-PPMP	Apoptosis	Cancer
L-threo-PPMP is a GlcT (UDP-Glc: Ceramide β1,1glucosyltransferase) inhibitor. L-threo-PPMP inhibits glycosphingolipid biosynthesis and induces apoptosis. L-threo-PPMP has anti-cancer activity .

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM .

HY-13302

CP-547632	VEGFR FGFR	Cancer
CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy .

HY-13302B

CP-547632 hydrochloride	VEGFR FGFR	Cancer
CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy .

HY-13302C

CP-547632 TFA	VEGFR FGFR	Cancer
CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy .

HY-10331

Regorafenib Maximum Cited Publications 47 Publications Verification BAY 73-4506	VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie	Cancer
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .

HY-10331A

Regorafenib monohydrate Maximum Cited Publications 47 Publications Verification BAY 73-4506 monohydrate	VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie	Cancer
Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .

HY-136121

Tubulin inhibitor 6	Microtubule/Tubulin	Cancer
Tubulin inhibitor 6 (Compound 14b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 6 inhibits tubulin polymerization with an IC₅₀ of 0.87 μM. Tubulin inhibitor 6 inhibits K562 cell growth with an IC₅₀ of 840 nM .

HY-136123

Tubulin inhibitor 8	Microtubule/Tubulin	Cancer
Tubulin inhibitor 8 (Compound 33b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 8 inhibits tubulin polymerization with an IC₅₀ of 0.73 μM. Tubulin inhibitor 8 inhibits K562 cell growth with an IC₅₀ of 14 nM .

HY-136122

Tubulin inhibitor 7	Microtubule/Tubulin	Cancer
Tubulin inhibitor 7 (Compound 33c) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 7 inhibits tubulin polymerization with an IC₅₀ of 0.52 μM. Tubulin inhibitor 7 inhibits K562 cell growth with an IC₅₀ of 11 nM .

HY-10331B

Regorafenib mesylate BAY 73-4506 mesylate	VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie	Cancer
Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC₅₀ values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .

HY-116107

AG311

Necroptosis Cancer

AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .

AG311	Necroptosis	Cancer
AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .

HY-W020790

Sialyl-Lewis X sLeX	Endogenous Metabolite	Inflammation/Immunology
Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM .

3'-Hydroxypterostilbene 1 Publications Verification	Structural Classification Stilbenes Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer Sphaerophysa salsula	Apoptosis Autophagy
3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC₅₀s of 9.0, 40.2 and 70.9 µM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer .

Sialyl-Lewis X sLeX	Structural Classification Polysaccharides Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite
Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Colo-205

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products